Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists

Radiation Oncology

Volumn 10, Issue 1, 2015, Pages

  Shakespeare, Thomas P ^a,b  

^a North Coast Cancer Institute   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Decision making; Positron emission tomography; Prostate cancer; Prostate specific membrane antigen; Radiation oncologist; Radiotherapy; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC IMAGING; ELECTRONIC MEDICAL RECORD; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RADIATION ONCOLOGIST; VERY ELDERLY; BIOSYNTHESIS; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; BIOMARKERS, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PRACTICE PATTERNS, PHYSICIANS'; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY;

EID: 84960406964     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/s13014-015-0548-8     Document Type: Article

References (7)

1. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
2. Yu CY, Desai B, Ji L, Groshen S, Jadvar H. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging. 2014;4:580-601.
3. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-40.
4. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31:144-54.
5. Demirkol MO, Acar O, Ucar B, Ramazanoglu SR, Saglican Y, Esen T. Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision-making process. Prostate. 2015;75:748-57.
6. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of Hybrid 68Ga-PSMA-Ligand PET/CT in 248 Patients with Biochemical Recurrence after Radical Prostatectomy. J Nucl Med. 2015;56:668-74.
7. Bhattacharya IS, Woolf DK, Hughes RJ, Shah N, Harrison M, Ostler PJ, et al. Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease. Br J Radiol. 2015;88:1048.